Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: The diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005)

Archives of Internal Medicine

Volumn 169, Issue 14, 2009, Pages 1307-1316

  Nathan, David M ^a   Zinman, Bernard ^b   Cleary, Patricia A ^c   Backlund, Jye Yu C ^c   Genuth, Saul ^d   Miller, Rachel ^e   Orchard, Trevor J ^e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MOUNT SINAI HOSPITAL   (Canada)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN;

ADOLESCENT; ADULT; AMPUTATION; ARTICLE; BLINDNESS; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COHORT ANALYSIS; COMA; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DISEASE COURSE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INTENSIVE CARE; KIDNEY FUNCTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBESITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; REPEATED DRUG DOSE; RETINA MACULA EDEMA; SEIZURE; SELF MONITORING; UNITED STATES;

ADOLESCENT; ADULT; BLOOD GLUCOSE; CANADA; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETIC KETOACIDOSIS; HUMANS; HYPOGLYCEMIA; INSULIN; LONGITUDINAL STUDIES; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES; WEIGHT GAIN; YOUNG ADULT;

EID: 67749084303     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2009.193     Document Type: Article

References (31)

1. The DCCT Research Group. The Diabetes Control and Complications Trial (DCCT): design and methodologic considerations for the feasibility phase. Diabetes. 1986;35(5):530-545.
2. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Epidemiology of Diabetes Interventions and Complications (EDIC): design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care. 1999;22(1):99-111.
3. Reichard P, Nilsson B-Y, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329(5):304-309.
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
5. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342(6):381-389.
6. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290(16):2159-2167.
7. Nathan DM, Cleary PA, Backlund JY, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in type 1 diabetes mellitus. N Engl J Med. 2005;353(25):2643-2653.
8. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR. The changing natural history of nephropathy in type 1 diabetes. Am J Med. 1985;78(5):785-794.
9. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, IX: four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1989;107(2):237-243.
10. Lee ET, Keen H, Bennett PH, Fuller JH, Lu M. Follow-up of the WHO multinational study of vascular disease in diabetes: general description and morbidity. Diabetologia. 2001;44(suppl 2):S3-S13.
11. EURODIAB IDDM Complications Study Group. Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. Diabetologia. 1994;37(3):278-285.
12. Walsh MG, Zgibor J, Borch-Johnsen K, Orchard TJ; DiaComp Investigators. A multinational assessment of complications in type 1 diabetes: the DiaMond substudy of complications (DiaComp) level 1. Diab Vasc Dis Res. 2006;3(2):84-92.
13. Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ. The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes. 2006;55(5):1463-1469.
14. Hovind P, Tarnow L, Rossing K, et al. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care. 2003;26(4):1258-1264.
15. Nordwall M, Bojestig M, Arnqvist HJ, Ludvigsson J. Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of type 1 diabetes: the Linköping Diabetes Complications Study. Diabetologia. 2004;47(7):1266-1272.
16. Finne P, Reunanen A, Stenman S, Groop PH, Grönhagen-Riska C. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA. 2005;294(14):1782-1787.
17. DCCT Research Group. Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care. 1995;18(3):361-376.
18. American Diabetes Association. Implications of the Diabetes Control and Complications Trial. Diabetes. 1993;42(11):1555-1558.
19. Orchard TJ, Dorman JS, Maser RE, et al. Factors associated with avoidance of severe complications after 25 yr of IDDM: Pittsburgh Epidemiology of Diabetes Complications Study I. Diabetes Care. 1990;13(7):741-747.
20. Wagener DK, Sacks JM, LaPorte RE, Macgregor JM. The Pittsburgh Study of insulin-dependent diabetes mellitus: risk for diabetes among relatives of IDDM. Diabetes. 1982;31(2):136-144.
21. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care. 2008;31(suppl 1):S12-S54.
22. Steffes M, Cleary P, Goldstein D, et al; The DCCT/EDIC Research Group. Hemoglobin A1c measurements over nearly two decades: sustaining comparable values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study. Clin Chem. 2005;51(4):753-758.
23. Early Therapy Diabetic Retinopathy Study (ETDRS) Manual of Operations. Springfield, VA: National Technical Information Service; 1985. NTIS accession No. PB85223006.
24. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. Arch Ophthalmol. 1995;113(1):36-51.
25. Orchard TJ, Dorman JS, Maser RE, et al. Prevalence of complications in IDDM by sex and duration: Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes. 1990;39(9):1116-1124.
26. Prince CT, Becker DJ, Costacou T, Miller RG, Orchard TJ. Changes in glycaemic control and risk of coronary artery disease in type 1 diabetes mellitus: findings from the Pittsburgh Epidemiology of Diabetes Complications Study (EDC). Diabetologia. 2007;50(11):2280-2288.
27. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York, NY: John Wiley; 1981:38-46.
28. Odell PM, Anderson KM, D'Agostino RB. Maximum likelihood estimation for interval-censored data using a Weibull-based accelerated failure time model. Biometrics. 1992;48(3):951-959.
29. Klein R, Klein BE, Moss SE. Epidemiology of proliferative diabetic retinopathy. Diabetes Care. 1992;15(12):1875-1891.
30. Rossing P, Rossing K, Jacobsen P, Parving H-H. Unchanged incidence of diabetic nephropathy in IDDM patients. Diabetes. 1995;44(7):739-743.
31. Moss SE, Meuer SM, Klein R, Hubbard LD, Brothers RJ, Klein BE. Are seven standard photographic fields necessary for classification of diabetic retinopathy. Invest Ophthalmol Vis Sci. 1989;30(5):823-828.